BNC 101

Drug Profile

BNC 101

Alternative Names: BNC-101; ET-101

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Bionomics; Eclipse Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action LGR5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Solid tumours
  • No development reported Cancer

Most Recent Events

  • 01 Mar 2016 Phase-I clinical trials in Colorectal cancer (Metastatic disease) in Australia (Parenteral) (NCT02726334)
  • 19 Oct 2015 Discontinued for Solid tumours in Australia (Parenteral)
  • 31 Aug 2015 The US FDA approves IND application for BNC 101 in Colorectal and pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top